Article
The discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.
Researchers have recently discovered a new type of small-cell lung cancer (SCLC), and the discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.
The discovery of this previously unnoticed form of the disease occurred as a result of a study of SCLC that applied domain-focused CRISPR screening, a gene-editing tool, to human cancer cell lines in order to identify the transcription factor, POU2F3, as a powerful dependency in a subset of SCLC.
“These data reveal POU2F3 as a cell identity determinant and a dependency in a tuft cell-like variant of SCLC, which may reflect a previously unrecognized cell of origin or a trans-differentiation event in this disease,” concluded the study.
Click to continue reading on The American Journal of Managed Care.